Meeting
2015 ASCO Annual Meeting
Impact of older age on chemotherapy toxicity and quality of life in women with advanced or recurrent cervical cancer: A NRG Oncology-GOG Ancillary Study.
Authors
Emily Meichun Ko
University of Pennsylvania, Philadelphia, PA
Emily Meichun Ko , James Java , Kathryn Schmitz , Marcus Randall , Jeffrey Bloss , Gini F. Fleming , David H. Moore , Bradley J. Monk , Hyman B. Muss , Linda Van Le
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5604)
DOI
10.1200/jco.2015.33.15_suppl.5604
Abstract #
5604
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
First Author: Ronnie Shapira-Frommer
Poster
2018 ASCO Annual Meeting
Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).
First Author: Andres Redondo
Poster
2016 ASCO Annual Meeting
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.
First Author: Milena Bruzzone